It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chemical tools to monitor drug-target engagement of endogenously expressed protein kinases are highly desirable for preclinical target validation in drug discovery. Here, we describe a chemical genetics strategy to selectively study target engagement of endogenous kinases. By substituting a serine residue into cysteine at the DFG-1 position in the ATP-binding pocket, we sensitize the non-receptor tyrosine kinase FES towards covalent labeling by a complementary fluorescent chemical probe. This mutation is introduced in the endogenous FES gene of HL-60 cells using CRISPR/Cas9 gene editing. Leveraging the temporal and acute control offered by our strategy, we show that FES activity is dispensable for differentiation of HL-60 cells towards macrophages. Instead, FES plays a key role in neutrophil phagocytosis via SYK kinase activation. This chemical genetics strategy holds promise as a target validation method for kinases.
Chemical tools to monitor drug-target engagement of endogenous enzymes are essential for preclinical target validation. Here, the authors present a chemical genetics strategy to study target engagement of endogenous kinases, achieving specific labeling and inactivation of FES kinase to provide insights into FES’ role in neutrophil phagocytosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Leiden Institute of Chemistry, Leiden University & Oncode Institute, Department of Molecular Physiology, Leiden, The Netherlands (GRID:grid.5132.5) (ISNI:0000 0001 2312 1970)
2 PamGene International BV, ‘s-Hertogenbosch, The Netherlands (GRID:grid.5132.5)
3 Leiden Institute of Chemistry, Leiden University, Department of Bio-organic Synthesis, Leiden, The Netherlands (GRID:grid.5132.5) (ISNI:0000 0001 2312 1970)
4 Leiden Academic Centre for Drug Research, Leiden University, Department of Drug Discovery & Safety, Leiden, The Netherlands (GRID:grid.5132.5) (ISNI:0000 0001 2312 1970)
5 Covalution Biosciences BV, Ravenstein, The Netherlands (GRID:grid.5132.5)